Director at Coeptis (COEP) gains shares via option exercise and grant

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings, Inc. director Philippe Deschamps increased his direct common stock holdings through equity awards. On February 11, 2026, he acquired 5,700 shares of common stock by exercising stock options at $10.56 per share, classified as an exercise or conversion of a derivative security.

On the same date, he also received a grant of 3,250 shares of restricted stock at a stated price of $0. This restricted stock was issued in an option exchange program in which he surrendered underwater options in return for restricted shares. Following these transactions, he directly beneficially owned 8,950 shares of Coeptis common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Deschamps Philippe

Role Director

Type	Security	Shares	Price	Value
Exercise	Common stock	5,700	$10.56	$60K
Grant/Award	Common Stock	3,250	$0.00	--

Holdings After Transaction: Common stock — 8,950 shares (Direct); Common Stock — 8,950 shares (Direct)

Footnotes (1)

1. Represents the exercise price of shares purchased upon exercise of stock options. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Deschamps Philippe

(Last) (First) (Middle)

105 BRADFORD ROAD, SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		5,700	A	$10.56(1)	8,950	D
Common Stock	02/11/2026		A		3,250	A	$0(2)	8,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

	/s/ Philippe Deschamps	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Coeptis (COEP) director Philippe Deschamps report in this Form 4?

Philippe Deschamps reported acquiring Coeptis common stock through an option exercise and a restricted stock grant. He exercised options for 5,700 shares and received 3,250 restricted shares, ending with direct beneficial ownership of 8,950 Coeptis Therapeutics Holdings, Inc. common shares.

How many Coeptis (COEP) shares did Philippe Deschamps acquire via option exercise?

Deschamps acquired 5,700 Coeptis common shares through an option exercise. The transaction used code "M," indicating exercise or conversion of a derivative security, at an exercise price of $10.56 per share, increasing his directly held common stock position in the company.

What is the nature of the restricted stock grant reported for Coeptis (COEP)?

The Form 4 shows a grant of 3,250 shares of restricted Coeptis common stock at a stated price of $0. The footnote explains this grant occurred in an option exchange program where Deschamps surrendered underwater stock options in exchange for restricted stock.

How many Coeptis (COEP) shares does Philippe Deschamps own after these transactions?

After the reported transactions, Deschamps beneficially owns 8,950 shares of Coeptis common stock directly. This total reflects both the 5,700 shares obtained through the stock option exercise and the 3,250-share restricted stock grant reported in the Form 4 filing.

Were the Coeptis (COEP) transactions open-market buys or derivative-related acquisitions?

The reported Coeptis share changes are derivative-related acquisitions, not open-market purchases. One transaction is an option exercise (code "M") and the other is a grant or award of restricted stock (code "A"), both increasing Deschamps’ direct common stock holdings.